Adial Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • AZR

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.80
  • (As of Wednesday Closing)

Adial Pharmaceuticals General Information

Description

Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.

Contact Information

Website
www.adial.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4870 Sadler Road
  • Suite 300
  • Glen Allen, VA 23060
  • United States
+1 (804)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4870 Sadler Road
  • Suite 300
  • Glen Allen, VA 23060
  • United States
+1 (804)

Adial Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adial Pharmaceuticals Stock Performance

As of 18-Nov-2026, Adial Pharmaceuticals’s stock price is $3.80. Its current market cap is $54.3M with 14.3M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.80 $3.67 $1.31 - $8.22 $54.3M 14.3M 49.9K -$17.99

Adial Pharmaceuticals Financials Summary

As of 30-Sep-2026, Adial Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 20,351 1,257 1,335 1,950
Revenue 0 0 0 0
EBITDA (120,888) (8,126) (13,376) (7,071)
Net Income (120,570) (7,977) (13,197) (5,123)
Total Assets 22,528 6,673 5,044 4,737
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adial Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adial Pharmaceuticals‘s full profile, request access.

Request a free trial

Adial Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases
Pharmaceuticals
Glen Allen, VA
6 As of 2025

North Chesterfield, VA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adial Pharmaceuticals Competitors (9)

One of Adial Pharmaceuticals’s 9 competitors is Indivior, a Corporate Backed or Acquired company based in North Chesterfield, VA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Indivior Corporate Backed or Acquired North Chesterfield, VA
AVEO Oncology Formerly VC-backed Boston, MA
Blueprint Medicines Formerly VC-backed Cambridge, MA
Alkermes Formerly VC-backed Dublin, Ireland
Aptevo Therapeutics Corporation Seattle, WA
You’re viewing 5 of 9 competitors. Get the full list »

Adial Pharmaceuticals Patents

Adial Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260345557-A1 Ondansetron treatment of alcohol use disorder Pending 05-Jul-2024
WO-2026011119-A1 Ondansetron treatment of alcohol use disorder Pending 05-Jul-2024
EP-3372532-A1 Carriage for an automatic dispenser of prepared food products, notably pizza Inactive 07-Mar-2017
US-20180257862-A1 Carriage for an automatic dispenser of prepared food products, notably pizza Inactive 07-Mar-2017
FR-3063718-A1 Trolley for automatic dispenser of prepared food products, in particular pizza Active 07-Mar-2017 B65G1/137
To view Adial Pharmaceuticals’s complete patent history, request access »

Adial Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adial Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adial Pharmaceuticals‘s full profile, request access.

Request a free trial

Adial Pharmaceuticals Acquisitions (2)

Adial Pharmaceuticals’s most recent deal was a Merger/Acquisition with Azora Therapeutics. The deal was made on 11-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Azora Therapeutics 11-Jun-2026 Merger/Acquisition Drug Discovery
Purnovate 26-Jan-2021 Merger/Acquisition Drug Discovery
To view Adial Pharmaceuticals’s complete acquisitions history, request access »

Adial Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.09 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Adial Pharmaceuticals’s complete esg history, request access »

Adial Pharmaceuticals Exits (1)

Adial Pharmaceuticals’s most recent exit was on 26-Jan-2021 from Purnovate. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Purnovate 26-Jan-2021 Completed
To view Adial Pharmaceuticals’s complete exits history, request access »

Adial Pharmaceuticals FAQs

  • When was Adial Pharmaceuticals founded?

    Adial Pharmaceuticals was founded in 2010.

  • Where is Adial Pharmaceuticals headquartered?

    Adial Pharmaceuticals is headquartered in Glen Allen, VA.

  • What is the size of Adial Pharmaceuticals?

    Adial Pharmaceuticals has 6 total employees.

  • What industry is Adial Pharmaceuticals in?

    Adial Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Adial Pharmaceuticals a private or public company?

    Adial Pharmaceuticals is a Public company.

  • What is Adial Pharmaceuticals’s stock symbol?

    The ticker symbol for Adial Pharmaceuticals is AZR.

  • What is the current stock price of Adial Pharmaceuticals?

    As of 18-Nov-2026 the stock price of Adial Pharmaceuticals is $3.80.

  • What is the current market cap of Adial Pharmaceuticals?

    The current market capitalization of Adial Pharmaceuticals is $54.3M.

  • Who are Adial Pharmaceuticals’s competitors?

    Indivior, AVEO Oncology, Blueprint Medicines, Alkermes, and Aptevo Therapeutics are some of the 9 competitors of Adial Pharmaceuticals.

  • What is Adial Pharmaceuticals’s annual earnings per share (EPS)?

    Adial Pharmaceuticals’s EPS for 12 months was -$17.99.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process